Expression of HLA-DR in Cytotoxic T Lymphocytes: A Validated Predictive Biomarker and a Potential Therapeutic Strategy in Breast Cancer

SIMPLE SUMMARY: More than 50% of breast cancer (BC) patients selected for neoadjuvant chemotherapy (NACT) are subjected to at least a 6-month regimen of this treatment without a clear benefit, probably delaying more effective therapeutic strategies and being exposed to potential treatment-associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Saraiva, Diana P., Azeredo-Lopes, Sofia, Antunes, Ana, Salvador, Rute, Borralho, Paula, Assis, Beatriz, Pereira, Isabel L., Seabra, Zita, Negreiros, Ida, Jacinto, António, Braga, Sofia, Cabral, M. Guadalupe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345089/
https://www.ncbi.nlm.nih.gov/pubmed/34359741
http://dx.doi.org/10.3390/cancers13153841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345089/
https://www.ncbi.nlm.nih.gov/pubmed/34359741
http://dx.doi.org/10.3390/cancers13153841

Ejemplares similares